Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
Table of Contents

                 
    As of December 31, 2006  
          Pro Forma
 
    Actual     as Adjusted(1)(2)  
 
Balance Sheet Data:
               
Cash and cash equivalents and investment securities, available-for-sale
  $ 34,413,603     $ 99,523,603  
Working capital
    29,645,294       94,755,294  
Total assets
    36,809,984       101,919,984  
Redeemable convertible preferred stock
    45,896,934        
Deficit accumulated during the development stage
    (49,168,004 )     (49,168,004 )
Total stockholders’ equity (deficit)
    (15,846,922 )     95,160,012  
 
(1) Does not include $10.0 million borrowed in March 2007 under our credit and security agreement entered into with Merrill Lynch Capital in December 2006. An additional $7.0 million is available for future borrowings under the terms of, and subject to the conditions in, the credit and security agreement. See Note 3 of Notes to Financial Statements.
 
(2) Each $1.00 increase or decrease in the assumed initial public offering price of $12.00 (the mid-point of the price range set forth on the cover page of this prospectus) would increase or decrease, respectively, the amount of cash and cash equivalents and securities available-for-sale, working capital, total assets and total stockholders’ equity by $5.6 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us.

8